EP300 and neoplasm: CREBBP/EP300 mutations promoted the tumor progression of DLBCL through constitutive activation of the BCL6 oncoprotein, functional inactivation of p53 tumor suppressor activity, and activation of the NOTCH pathway by suppressing histone acetylation [13, 19].